[424B5] AEye, Inc. Prospectus Supplement (Debt Securities)
On 24 Jul 2025 AEye, Inc. (Nasdaq: LIDR) filed Amendment No. 3 to its 424(b)(5) prospectus supplements for its Form S-3 at-the-market (ATM) equity program with A.G.P./Alliance Global Partners. The amendment raises the maximum aggregate offering price that may be sold under the Sales Agreement from $2.6 million to $23.728 million, equal to one-third of the company’s $71.2 million public float, as permitted by General Instruction I.B.6.
AEye has already issued $14.993 million of securities under this rule in the last 12-month period; combined future sales cannot surpass the updated $23.728 million cap unless a further supplement is filed. Key metrics disclosed: 25.42 million shares outstanding, of which 24.38 million are held by non-affiliates; last reported share price $2.92. The company continues to qualify as an “emerging growth” and “smaller reporting” company, benefiting from reduced reporting requirements. Investors are directed to previously disclosed risk factors for additional considerations.
Il 24 luglio 2025 AEye, Inc. (Nasdaq: LIDR) ha presentato la Terza Modifica ai supplementi al prospetto 424(b)(5) relativi al suo programma azionario at-the-market (ATM) del modulo S-3 con A.G.P./Alliance Global Partners. La modifica aumenta il prezzo massimo aggregato dell’offerta che può essere venduto ai sensi dell’Accordo di Vendita da 2,6 milioni di dollari a 23,728 milioni di dollari, pari a un terzo della flottante pubblica da 71,2 milioni di dollari della società, come consentito dall’Istruzione Generale I.B.6.
AEye ha già emesso titoli per un valore di 14,993 milioni di dollari ai sensi di questa regola negli ultimi 12 mesi; le vendite future combinate non possono superare il nuovo limite di 23,728 milioni di dollari a meno che non venga presentato un ulteriore supplemento. Metriche chiave divulgate: 25,42 milioni di azioni in circolazione, di cui 24,38 milioni detenute da non affiliati; ultimo prezzo azionario riportato 2,92 dollari. La società continua a qualificarsi come “emerging growth” e “smaller reporting” company, beneficiando di requisiti di rendicontazione ridotti. Gli investitori sono invitati a consultare i fattori di rischio precedentemente divulgati per ulteriori informazioni.
El 24 de julio de 2025, AEye, Inc. (Nasdaq: LIDR) presentó la Enmienda N° 3 a sus suplementos del prospecto 424(b)(5) para su programa de acciones at-the-market (ATM) del formulario S-3 con A.G.P./Alliance Global Partners. La enmienda eleva el precio máximo agregado de la oferta que puede venderse bajo el Acuerdo de Venta de 2,6 millones de dólares a 23,728 millones de dólares, equivalente a un tercio del flotante público de 71,2 millones de dólares de la empresa, según lo permitido por la Instrucción General I.B.6.
AEye ya ha emitido valores por un total de 14,993 millones de dólares bajo esta regla en los últimos 12 meses; las ventas futuras combinadas no pueden superar el límite actualizado de 23,728 millones de dólares a menos que se presente un suplemento adicional. Métricas clave divulgadas: 25,42 millones de acciones en circulación, de las cuales 24,38 millones están en manos de no afiliados; último precio reportado por acción 2,92 dólares. La empresa sigue calificando como una compañía de “emerging growth” y “smaller reporting”, beneficiándose de requisitos de reporte reducidos. Se recomienda a los inversores revisar los factores de riesgo previamente divulgados para consideraciones adicionales.
2025년 7월 24일, AEye, Inc. (나스닥: LIDR)는 A.G.P./Alliance Global Partners와 함께하는 Form S-3의 at-the-market(ATM) 주식 프로그램에 대한 424(b)(5) 설명서 보충서 제3차 수정안을 제출했습니다. 이번 수정안은 판매 계약에 따른 최대 총 공모가액을 260만 달러에서 2,372.8만 달러로 상향 조정했으며, 이는 회사의 7,120만 달러 공개 유통 주식의 3분의 1에 해당하며, 일반 지침 I.B.6에 따라 허용됩니다.
AEye는 지난 12개월 동안 이 규칙에 따라 이미 1,499.3만 달러 상당의 증권을 발행했으며, 향후 판매액은 추가 보충서 제출 없이는 갱신된 2,372.8만 달러 한도를 초과할 수 없습니다. 주요 지표: 발행 주식 수 2,542만 주, 이 중 2,438만 주는 비계열사 보유; 최근 보고된 주가 2.92달러. 회사는 계속해서 “신흥 성장 기업(emerging growth)” 및 “소규모 보고 기업(smaller reporting)”으로 분류되어 보고 요건이 완화됩니다. 투자자들은 추가 고려 사항을 위해 이전에 공개된 위험 요소를 참조할 것을 권고합니다.
Le 24 juillet 2025, AEye, Inc. (Nasdaq : LIDR) a déposé l’Amendement n° 3 à ses suppléments de prospectus 424(b)(5) pour son programme d’actions en vente au marché (ATM) Formulaire S-3 avec A.G.P./Alliance Global Partners. Cet amendement augmente le prix maximum global de l’offre pouvant être vendu dans le cadre de l’Accord de Vente, passant de 2,6 millions de dollars à 23,728 millions de dollars, soit un tiers du flottant public de 71,2 millions de dollars de la société, conformément à l’Instruction Générale I.B.6.
AEye a déjà émis pour 14,993 millions de dollars de titres selon cette règle au cours des 12 derniers mois ; les ventes futures combinées ne peuvent dépasser le plafond actualisé de 23,728 millions de dollars sauf dépôt d’un supplément supplémentaire. Indicateurs clés divulgués : 25,42 millions d’actions en circulation, dont 24,38 millions détenues par des non-affiliés ; dernier cours signalé de 2,92 dollars. La société continue de se qualifier comme une entreprise « emerging growth » et « smaller reporting », bénéficiant d’exigences de reporting réduites. Les investisseurs sont invités à consulter les facteurs de risque précédemment divulgués pour des considérations supplémentaires.
Am 24. Juli 2025 reichte AEye, Inc. (Nasdaq: LIDR) die Änderung Nr. 3 zu seinen 424(b)(5)-Prospektergänzungen für sein Form S-3 At-the-Market-(ATM) Aktienprogramm bei A.G.P./Alliance Global Partners ein. Die Änderung erhöht den maximalen Gesamtangebotswert, der gemäß dem Verkaufsvertrag verkauft werden darf, von 2,6 Millionen US-Dollar auf 23,728 Millionen US-Dollar, was einem Drittel des 71,2 Millionen US-Dollar öffentlichen Streubesitzes des Unternehmens entspricht, wie in der Allgemeinen Anweisung I.B.6 erlaubt.
AEye hat in den letzten 12 Monaten bereits Wertpapiere im Wert von 14,993 Millionen US-Dollar gemäß dieser Regel ausgegeben; künftige kombinierte Verkäufe dürfen die aktualisierte Obergrenze von 23,728 Millionen US-Dollar nicht überschreiten, es sei denn, es wird eine weitere Ergänzung eingereicht. Wichtige Kennzahlen: 25,42 Millionen ausstehende Aktien, davon 24,38 Millionen im Besitz von Nicht-Affiliates; zuletzt gemeldeter Aktienkurs 2,92 US-Dollar. Das Unternehmen qualifiziert sich weiterhin als "emerging growth" und "smaller reporting" Unternehmen und profitiert von reduzierten Berichtspflichten. Investoren werden auf zuvor veröffentlichte Risikofaktoren für weitere Überlegungen hingewiesen.
- Increased capital flexibility: authority to sell up to $23.728 M of common stock provides a readily accessible funding source.
- Regulatory compliance affirmed: filing demonstrates adherence to Form S-3 I.B.6 limits and ongoing Nasdaq listing.
- Dilution risk: issuance of additional stock—up to one-third of public float—could dilute existing shareholders.
- Significant prior sales: $14.993 M already sold in last 12 months means only about $8.7 M capacity remains before a new supplement is needed.
Insights
TL;DR: Amendment ups ATM capacity to $23.7 M, improving liquidity but adding dilution risk; overall impact is neutral.
The filing expands AEye’s at-the-market shelf capacity to one-third of public float, giving management flexibility to raise up to $8.7 M more before reaching the 12-month cap (after $15 M already sold). Additional cash could support operations without a traditional follow-on offering, but incremental issuance at roughly $3/share may materially dilute existing holders. No use-of-proceeds update or financial guidance is provided, limiting visibility on capital needs. Because the amendment simply adjusts the ceiling within regulatory limits and does not mandate immediate issuance, I view the disclosure as neutral for valuation in the near term.
Il 24 luglio 2025 AEye, Inc. (Nasdaq: LIDR) ha presentato la Terza Modifica ai supplementi al prospetto 424(b)(5) relativi al suo programma azionario at-the-market (ATM) del modulo S-3 con A.G.P./Alliance Global Partners. La modifica aumenta il prezzo massimo aggregato dell’offerta che può essere venduto ai sensi dell’Accordo di Vendita da 2,6 milioni di dollari a 23,728 milioni di dollari, pari a un terzo della flottante pubblica da 71,2 milioni di dollari della società, come consentito dall’Istruzione Generale I.B.6.
AEye ha già emesso titoli per un valore di 14,993 milioni di dollari ai sensi di questa regola negli ultimi 12 mesi; le vendite future combinate non possono superare il nuovo limite di 23,728 milioni di dollari a meno che non venga presentato un ulteriore supplemento. Metriche chiave divulgate: 25,42 milioni di azioni in circolazione, di cui 24,38 milioni detenute da non affiliati; ultimo prezzo azionario riportato 2,92 dollari. La società continua a qualificarsi come “emerging growth” e “smaller reporting” company, beneficiando di requisiti di rendicontazione ridotti. Gli investitori sono invitati a consultare i fattori di rischio precedentemente divulgati per ulteriori informazioni.
El 24 de julio de 2025, AEye, Inc. (Nasdaq: LIDR) presentó la Enmienda N° 3 a sus suplementos del prospecto 424(b)(5) para su programa de acciones at-the-market (ATM) del formulario S-3 con A.G.P./Alliance Global Partners. La enmienda eleva el precio máximo agregado de la oferta que puede venderse bajo el Acuerdo de Venta de 2,6 millones de dólares a 23,728 millones de dólares, equivalente a un tercio del flotante público de 71,2 millones de dólares de la empresa, según lo permitido por la Instrucción General I.B.6.
AEye ya ha emitido valores por un total de 14,993 millones de dólares bajo esta regla en los últimos 12 meses; las ventas futuras combinadas no pueden superar el límite actualizado de 23,728 millones de dólares a menos que se presente un suplemento adicional. Métricas clave divulgadas: 25,42 millones de acciones en circulación, de las cuales 24,38 millones están en manos de no afiliados; último precio reportado por acción 2,92 dólares. La empresa sigue calificando como una compañía de “emerging growth” y “smaller reporting”, beneficiándose de requisitos de reporte reducidos. Se recomienda a los inversores revisar los factores de riesgo previamente divulgados para consideraciones adicionales.
2025년 7월 24일, AEye, Inc. (나스닥: LIDR)는 A.G.P./Alliance Global Partners와 함께하는 Form S-3의 at-the-market(ATM) 주식 프로그램에 대한 424(b)(5) 설명서 보충서 제3차 수정안을 제출했습니다. 이번 수정안은 판매 계약에 따른 최대 총 공모가액을 260만 달러에서 2,372.8만 달러로 상향 조정했으며, 이는 회사의 7,120만 달러 공개 유통 주식의 3분의 1에 해당하며, 일반 지침 I.B.6에 따라 허용됩니다.
AEye는 지난 12개월 동안 이 규칙에 따라 이미 1,499.3만 달러 상당의 증권을 발행했으며, 향후 판매액은 추가 보충서 제출 없이는 갱신된 2,372.8만 달러 한도를 초과할 수 없습니다. 주요 지표: 발행 주식 수 2,542만 주, 이 중 2,438만 주는 비계열사 보유; 최근 보고된 주가 2.92달러. 회사는 계속해서 “신흥 성장 기업(emerging growth)” 및 “소규모 보고 기업(smaller reporting)”으로 분류되어 보고 요건이 완화됩니다. 투자자들은 추가 고려 사항을 위해 이전에 공개된 위험 요소를 참조할 것을 권고합니다.
Le 24 juillet 2025, AEye, Inc. (Nasdaq : LIDR) a déposé l’Amendement n° 3 à ses suppléments de prospectus 424(b)(5) pour son programme d’actions en vente au marché (ATM) Formulaire S-3 avec A.G.P./Alliance Global Partners. Cet amendement augmente le prix maximum global de l’offre pouvant être vendu dans le cadre de l’Accord de Vente, passant de 2,6 millions de dollars à 23,728 millions de dollars, soit un tiers du flottant public de 71,2 millions de dollars de la société, conformément à l’Instruction Générale I.B.6.
AEye a déjà émis pour 14,993 millions de dollars de titres selon cette règle au cours des 12 derniers mois ; les ventes futures combinées ne peuvent dépasser le plafond actualisé de 23,728 millions de dollars sauf dépôt d’un supplément supplémentaire. Indicateurs clés divulgués : 25,42 millions d’actions en circulation, dont 24,38 millions détenues par des non-affiliés ; dernier cours signalé de 2,92 dollars. La société continue de se qualifier comme une entreprise « emerging growth » et « smaller reporting », bénéficiant d’exigences de reporting réduites. Les investisseurs sont invités à consulter les facteurs de risque précédemment divulgués pour des considérations supplémentaires.
Am 24. Juli 2025 reichte AEye, Inc. (Nasdaq: LIDR) die Änderung Nr. 3 zu seinen 424(b)(5)-Prospektergänzungen für sein Form S-3 At-the-Market-(ATM) Aktienprogramm bei A.G.P./Alliance Global Partners ein. Die Änderung erhöht den maximalen Gesamtangebotswert, der gemäß dem Verkaufsvertrag verkauft werden darf, von 2,6 Millionen US-Dollar auf 23,728 Millionen US-Dollar, was einem Drittel des 71,2 Millionen US-Dollar öffentlichen Streubesitzes des Unternehmens entspricht, wie in der Allgemeinen Anweisung I.B.6 erlaubt.
AEye hat in den letzten 12 Monaten bereits Wertpapiere im Wert von 14,993 Millionen US-Dollar gemäß dieser Regel ausgegeben; künftige kombinierte Verkäufe dürfen die aktualisierte Obergrenze von 23,728 Millionen US-Dollar nicht überschreiten, es sei denn, es wird eine weitere Ergänzung eingereicht. Wichtige Kennzahlen: 25,42 Millionen ausstehende Aktien, davon 24,38 Millionen im Besitz von Nicht-Affiliates; zuletzt gemeldeter Aktienkurs 2,92 US-Dollar. Das Unternehmen qualifiziert sich weiterhin als "emerging growth" und "smaller reporting" Unternehmen und profitiert von reduzierten Berichtspflichten. Investoren werden auf zuvor veröffentlichte Risikofaktoren für weitere Überlegungen hingewiesen.
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-274546
AMENDMENT NO. 3 DATED JULY 24, 2025
To Prospectus Supplements dated December 30, 2024 and September 13, 2024
(To Prospectus dated September 15, 2023)
AEYE, INC.
Up to $23,728,000
Common Stock
This Amendment No. 3 to the Prospectus Supplements (the “Amendment”) amends and supplements the information in the prospectus, dated September 15, 2023 (the “Prospectus”), filed with the Securities and Exchange Commission as a part of our registration statement on Form S-3 (File No. 333-274546) (the “Registration Statement”), as previously supplemented by our prospectus supplements, dated September 13, 2024 and December 30, 2024, as amended by Amendment No. 1, dated January 7, 2025 and Amendment No. 2, dated January 23, 2025 (collectively, the “Prospectus Supplements,” and together with the Prospectus, the “Prior Prospectus”), relating to the offer and sale of shares of our common stock having an aggregate offering price of up to $2,600,000 pursuant to the terms of At Market Issuance Sales Agreement, dated September 12, 2024 (the “Sales Agreement”), with A.G.P./Alliance Global Partners (“A.G.P.”). This Amendment should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This Amendment is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus and any future amendments or supplements thereto.
We are filing this Amendment to amend the Prior Prospectus to update the maximum amount of shares that we are eligible to sell under our Registration Statement pursuant to the Sales Agreement under General Instruction I.B.6 of Form S-3. As a result of these limitations and the current public float of our common stock, and in accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $23,728,000 from time to time through A.G.P. In the event that we may sell additional amounts under the Sales Agreement in accordance with General Instruction I.B.6, we will file another prospectus supplement or amendment prior to making such additional sales. This Amendment amends and/or supplements only those sections of the Prior Prospectus as listed in this Amendment, and all other sections of the Prior Prospectus remain as is.
We are an “emerging growth company” and “smaller reporting company” as defined under U.S. federal securities laws and are subject to reduced public company reporting requirements. Our common stock is listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “LIDR.” The last sale price of our common stock, as reported on Nasdaq on July 24, 2025, was $2.92 per share.
As of July 24, 2025, the aggregate market value of our outstanding shares of common stock held by non-affiliates, or public float, was determined to be $71,186,514 based on 25,417,565 shares of common stock outstanding, of which 24,378,943 are held by non-affiliates, and at a price of $2.92 per share, the closing price of our common stock on July 24, 2025. In no event will the aggregate market value of securities sold by us or on our behalf pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar month period immediately prior to, and including, the date of any such sale exceed one-third of the aggregate market value of our shares of common stock held by non-affiliates, so long as the aggregate market value of our common stock held by non-affiliates is less than $75,000,000. During the prior 12 calendar month period that ends on, and includes, July 24, 2025, we have sold $14,993,326 of our securities pursuant to General Instruction I.B.6 of Form S-3.
Investing in our common stock involves a high degree of risk. See the “Risk Factors” section beginning on page S-6 of the Prospectus Supplement dated September 13, 2024 and the documents incorporated by reference into this Amendment and the Prior Prospectus, as they may be amended, updated or supplemented periodically in our reports filed with the Securities and Exchange Commission, before investing in our common stock.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this Amendment or the Prior Prospectus are truthful or complete. Any representation to the contrary is a criminal offense.
A.G.P.
The date of this Amendment No. 3 to the Prospectus Supplements is July 24, 2025
FAQ
How much stock can AEye (LIDR) now sell under its ATM program?
How much has AEye already raised via the ATM in the past 12 months?
What is AEye’s current public float and share price?
Will the amendment immediately dilute existing shareholders?
Why did AEye file Amendment No. 3 to its prospectus supplements?
